Transcatheter Aortic Valve Replacement Market Size, Share & Trends Analysis Report By Implantation Procedure (Transfemoral, Transapical), By Material, By Mechanism, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global transcatheter aortic valve replacement market size was estimated at USD 6.8 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2030. Factors driving the demand for TAVR include the rising prevalence of aortic valve stenosis (AS), increasing preference for minimally invasive procedures, and the growing geriatric population. According to an NCBI article published in February 2023, aortic stenosis is a structural heart condition characterized by a hemodynamic obstruction at the aortic valve, impeding blood flow. Among its various causes, calcific aortic stenosis (CAS) is the most prevalent and is estimated to affect approximately 12.6 million people globally. This includes a significant prevalence rate of 1,841 cases per 100,000 adults aged 70 and older, highlighting its impact on the aging population.

The global increase in the geriatric population is another key driver for the TAVR market. Older adults are more susceptible to cardiovascular diseases, including aortic valve stenosis, which necessitates effective treatment options like TAVR. According to the World Health Organization article published in October 2024, the proportion of the world's population over 60 years old is expected to double by 2050, reaching approximately 2.1 billion. The global population of individuals aged 80 years and older is projected to experience a threefold increase from 2020 to 2050, reaching an estimated total of 426 million. This demographic shift means a higher number of elderly patients will require medical interventions for age-related conditions such as aortic valve stenosis. The elderly are often high-risk candidates for conventional surgical procedures, making the less invasive TAVR a more viable and safer alternative. As a result, the growing geriatric population directly correlates with increased demand for TAVR, thereby driving market growth.

The rising adoption of TAVR systems for minimally invasive aortic stenosis treatment drives market growth. For instance, in July 2023, Onecera Medical achieved a significant milestone with the successful implantation of its Crea Aortic Valve, a Transcatheter Aortic Valve Replacement (TAVR) system designed to treat aortic stenosis. The Crea Aortic Valve features an innovative concave-convex structure, providing a stable and secure fit within the aortic annulus. Furthermore, its advanced differential radial force technology ensures variable radial forces depending on the valve’s position in the annulus and aorta, enhancing its performance and patient outcomes.

In addition, technological advancements in TAVR procedures significantly contribute to market growth. Innovations in valve design, catheter technologies, and imaging techniques have improved the safety, efficacy, and accessibility of TAVR. For instance, in January 2023, Abbott revealed that the U.S. FDA approved its newest TAVR system, Navitor, for treating individuals with aortic stenosis at high risk for undergoing open-heart surgery. Advanced imaging technologies, such as 3D echocardiography and CT scans, enable precise planning and execution of the procedure, minimizing complications. In addition, improvements in catheter technology allow for smaller, more flexible catheters, further reducing the procedure's invasiveness. These technological advancements enhance patient outcomes and expand the potential patient pool by making TAVR a feasible option for those previously deemed ineligible. Consequently, continuous innovation is a crucial driver of the TAVR market.

Furthermore, in May 2024, Edwards Lifesciences introduced the Sapien 3 Ultra Resilia valve in Europe, marking a milestone as the first TAVR system to integrate the company’s advanced Resilia tissue technology. Engineered to treat conditions like native calcific aortic stenosis and failed bioprosthetic valves, the system caters to patients across different surgical risk categories, including those deemed unsuitable for open-heart surgery. This innovative technology is poised to enhance patient outcomes by offering a minimally invasive alternative, encouraging greater adoption of TAVR systems, and driving market expansion.

Market Concentration & Characteristics

The TAVR market is highly innovative. Continuous advancements in valve design, imaging technologies, and minimally invasive techniques have significantly enhanced procedural safety and efficacy. These innovations have expanded patient eligibility and improved outcomes, driving substantial growth and establishing TAVR as a crucial alternative to traditional surgical methods for aortic valve replacement.

Mergers and acquisitions in the transcatheter aortic valve replacement industry are moderate. Companies are strategically consolidating to enhance their technological capabilities, expand their product portfolios, and increase market reach. These activities foster innovation and drive competition, ultimately benefiting the market by improving access to advanced TAVR solutions and accelerating growth within the industry.

Regulations have a high impact on the transcatheter aortic valve replacement industry. Stringent regulatory standards ensure the safety and efficacy of TAVR devices, influencing market dynamics. Regulatory approvals, such as those from the FDA and EMA, are crucial for product launches and market entry, shaping innovation and competition while ensuring that only high-quality, reliable devices are available to patients.

Product expansion in the TAVR market is high. For instance,in December 2024, Sahajanand Medical Technologies (SMT), a global innovator in cardiovascular solutions, introduced its Hydra Transcatheter Aortic Valve Replacement (TAVR) system in Mexico. This launch represents a significant advancement in SMT’s commitment to providing state-of-the-art, minimally invasive cardiac treatments to patients across the globe. This robust product expansion drives market growth, offering a wider range of options for different patient needs and expanding the applicability of TAVR procedures.

Regional expansion in the TAVR market is high. Companies are increasingly targeting emerging markets and expanding their presence in developed regions to capitalize on the growing demand for minimally invasive cardiac procedures. This expansion involves establishing new distribution channels, forming strategic partnerships, and obtaining regulatory approvals across various regions, enhancing global access to advanced TAVR technologies and driving overall market growth.

Implantation Procedures Insights

The transfemoral segment dominated this market with a revenue share of 51.5% in 2024. This approach involves inserting the valve through the femoral artery, offering a less invasive alternative to traditional open-heart surgery. Technological advancements, improved procedural outcomes, and expanding patient eligibility criteria drive the increasing adoption of transfemoral TAVR procedures. According to the Elsevier B.V. article published in December 2024, in a recent study evaluating 10,120 patients who underwent transfemoral TAVR across 10 heart centers, 7,165 patients (approximately 71%) preferred TF access. This method remains the dominant choice due to its reliable outcomes and the availability of advanced technologies that improve procedural safety.  The rise of alternatives like trans-radial secondary access (TR-SA) and TF access continues to be favored fuels market growth.

The transapical segment is anticipated to grow at the fastest CAGR over the forecast period. The transapical approach offers advantages such as a shorter distance between the left ventricular apex and the aortic valve, allowing greater maneuverability for operators during device implantation. Furthermore, it accommodates larger sheath diameters, facilitating smoother procedures. Various companies have innovated and introduced advanced transapical devices. According to the American College of Cardiology Foundation article published in May 2023, Edwards Lifesciences developed the Sapien device, which utilizes a balloon-expandable system. The Sapien device boasted extensive clinical experience and was the inaugural device approved for transapical implantation by regulatory authorities, highlighting its pioneering role in advancing minimally invasive treatment options for aortic valve replacement002E

Material Insights

Nitinol dominated this market and accounted for a 35.3% share in 2024. Nitinol, an alloy composed of nearly equal parts nickel and titanium, is widely used in TAVR devices due to its unique properties, such as non-magnetism, biocompatibility, flexibility, and fatigue resistance. These characteristics make it ideal for minimally invasive surgeries and implants, enhancing medical outcomes and driving segment growth. Notable TAVR devices incorporating nitinol in their frame structures include the Evolut R (Medtronic), Portico valve (St. Jude Medical, Inc.), and JenaValve (JenaValve Technology GmbH).

The cobalt chromium segment is anticipated to grow significantly over the forecast period. Cobalt-chromium is a durable, corrosion-resistant alloy commonly used in (TAVR) devices. Its strength, biocompatibility, and flexibility make it ideal for crafting valve frames that can withstand the high-pressure environment of the heart while ensuring long-term performance and safety. Due to its higher radiopacity and resilience compared to steel stents, which allow for a smaller mesh size and reduce the risk of thrombosis, cobalt-chromium stents also offer excellent biocompatibility. For example, Edwards Lifesciences' Sapien 3 device, the fourth generation in the balloon-expandable Sapien line, features a cobalt-chromium frame.

Mechanism Insights

The balloon-expandable segment held the largest market share of 55.7% in 2024. The balloon-expandable valve is the most widely used in TAVR procedures. Its non-repositionable, intra-annular design with a lower stent frame profile facilitates easier coronary access. In addition, the more steerable delivery method compared to self-expanding devices aids valve implantation in patients with complex vascular anatomies, such as a horizontal aorta (aortic angulation >60°). Numerous product launches are also driving the segment’s growth. For instance, in November 2024, Abbott announced the first patient procedures using its investigational balloon-expandable TAVI system for the treatment of symptomatic severe aortic stenosis. This system represents an initial step toward developing a software-guided, AI-integrated TAVI platform. Following clinical development and regulatory approval, this innovation will enhance Abbott's structural heart portfolio, providing physicians with an additional treatment option alongside the commercially available Navitor TAVI system.

The self-expandable segment is expected to grow significantly over the forecast period. Most self-expanding valves are supra-annular, providing a larger effective orifice area, lower gradients, and a reduced rate of severe prosthesis-patient mismatch (PPM). Moreover, major manufacturers continually focus on product development, driving segment growth. For instance, in August 2024, Boston Scientific received CE Mark approval for its Acurate Prime TAVR system, designed for patients with severe aortic stenosis. Building on the Acurate Neo2 platform, it features extended valve sizes for larger anatomies, an improved valve frame, and faster, controlled deployment. The self-expanding, supra-annular system is suitable for low-, intermediate-, and high-risk patients.

End Use Insights

Hospitals dominated this market with the largest revenue share of 88.0% in 2024, driven by the rising incidence of aortic stenosis and increased TAVR procedures. According to a Society of Thoracic Surgeons report in January 2024, nearly half of patients under 60 were receiving TAVR instead of SAVR by 2021. In addition, technological advancements in TAVR products and systems, improved healthcare infrastructure, and favorable reimbursement scenarios in both developed and developing countries are propelling segment growth. For instance, the Centers for Medicare & Medicaid Services covers TAVR for treating severe aortic stenosis under the “Coverage with Evidence Development” program.

Ambulatory surgical centers are projected to experience the fastest growth over the forecast period. These centers are cost-efficient and charge 45.0%-60.0% less than hospitals, with lower overhead, fixed costs, and shorter hospital stays. For instance, in October 2024, a new cardiovascular-focused ambulatory surgery center is set to open in the Short Pump area of Henrico, Virginia, thanks to a partnership between Compass Surgical Partners, Bon Secours Mercy Health, and AlignedCardio. Expected to be operational by late 2025, this state-of-the-art facility will offer top-tier outpatient cardiovascular treatments to patients throughout the Greater Richmond area, providing an alternative to traditional hospital admissions and overnight stays. The center's focus on convenience and high-quality care aims to improve patient experience while expanding access to essential cardiovascular services. This collaboration aims to improve cardiovascular care by expanding the availability of high-quality, patient-centered cardiovascular treatments in ambulatory surgical centers.

Regional Insights

North America dominated the transcatheter aortic valve replacement market and accounted for a 38.7% share in 2024, driven by its well-developed healthcare infrastructure and the increasing prevalence of conditions such as aortic stenosis (AS) and aortic regurgitation. The rising incidence of these disorders is expected to propel market expansion throughout the forecast period. According to the American Heart Association, Inc. article published in May 2024, in the U.S., the incidence of aortic stenosis is approximately 15.6 events per 100 individuals, which significantly contributes to the growing demand for Transcatheter Aortic Valve Replacement (TAVR) procedures. This high incidence rate is a key driver for the transcatheter aortic valve replacement industry, as healthcare providers and patients seek effective, less invasive solutions to manage this serious condition.

U.S. Transcatheter Aortic Valve Replacement Market Trends

The transcatheter aortic valve replacement market in the U.S. is anticipated to grow over the forecast period, with key players such as Edwards Lifesciences, Medtronic, and Boston Scientific flourishing. These companies drive market growth through strategic developments, including innovative product launches, FDA approvals, and partnerships. For instance, in August 2024, Edwards Lifesciences acquired JC Medical, a U.S.-based company specializing in transcatheter aortic valve replacement (TAVR), from Genesis MedTech, a Singapore-based firm, for an undisclosed sum. Their focus on technological advancements and expanding TAVR applications enhance procedural outcomes and expand patient access to this minimally invasive treatment.

Europe Transcatheter Aortic Valve Replacement Market Trends

Europe's transcatheter aortic valve replacement market is anticipated to experience the fastest growth during the forecast period. Several factors, rising CVD cases, including the increasing number of TAVR procedures, economic development, regulatory impacts, and new product launches in the EU, drive this expansion. According to a World Health Organization article published in May 2024, Cardiovascular diseases (CVDs) are the leading cause of disability and premature death in Europe, responsible for over 42.5% of all annual deaths, or approximately 10,000 fatalities daily. Among these, conditions like aortic stenosis significantly contribute to the disease burden.

The UK transcatheter aortic valve replacement market is growing over the forecast period. The increasing incidence of aortic stenosis and government initiatives drive the growth of the market. According to the Guy's and St Thomas Specialist Care article published in March 2024, about 400,000 individuals in the UK are affected by aortic stenosis, with its prevalence rising due to the aging population. Aortic stenosis is recognized as a progressive condition requiring timely intervention to manage its impact effectively.

The transcatheter aortic valve replacement market in Germany is expected to witness growth over the forecast period, driven by advancements in technology and increased minimally invasive procedures. According to the Deutsche Gesellschaft article published in July 2024 in Germany, transcatheter heart valve procedures' consistent growth and adoption resulted in 23,752 reported TAVR procedures in 2023. This steady increase reflects the growing reliance on minimally invasive solutions to address severe aortic stenosis, particularly among aging populations. The rising procedural volume underscores Germany's strong position as a key market for Transcatheter Aortic Valve Replacement (TAVR), driven by technological advancements and an increasing preference for less invasive treatment options.

France transcatheter aortic valve replacement market is growing over the forecast period. Increasing incidence of aortic stenosis and government initiatives drive the market's growth. According to the Elsevier B.V. article published in November 2024 , in France, approximately 363,574 individuals are reported to have aortic stenosis (AS), highlighting the growing burden of this condition within the population. With the increasing prevalence of AS, particularly among aging demographics, the demand for advanced treatment options like (TAVR) continues to rise. This trend underscores the importance of TAVR solutions in addressing the needs of patients with severe aortic stenosis and improving cardiovascular outcomes in France.

Asia Pacific Transcatheter Aortic Valve Replacement Market Trends

The transcatheter aortic valve replacement market in Asia Pacificis experiencing significant growth driven by several factors. Extrapolating western prevalence data to the Indian population suggests that approximately 250,000 to 300,000 patients with aortic stenosis could potentially benefit from TAVR. This number exceeds combined estimates from Europe and North America, highlighting substantial market potential for TAVR adoption in the Asia Pacific region. Moreover, a significant factor contributing to market expansion is the growing elderly population across the Asia Pacific region. According to the United Nations Economic and Social Commission for Asia and the Pacific, in 2023, Around 697 million people aged 60 and above reside in the Asia-Pacific region, making up nearly 60% of the world's senior population. This demographic is particularly vulnerable to (CVD).

China transcatheter aortic valve replacement market is growing over the forecast period. Increasing CVD cases and rising prevalence of aortic stenosis drives the growth of the market. According to the NCBI article published in December 2023 China faced a significant healthcare challenge, with approximately 330 million individuals affected by cardiovascular diseases (CVD) in 2022. This growing burden highlights the critical need for advanced treatment solutions, such as transcatheter aortic valve replacement (TAVR). As CVD prevalence continues to rise, particularly among aging populations, the demand for minimally invasive procedures like TAVR is expected to expand, driving growth in transcatheter aortic valve replacement industry.

The transcatheter aortic valve replacement market in Japan is expected to witness rapid growth, driven by advanced technology and evolving market factors, over the forecast. Innovations in valve designs and delivery systems enhance procedural outcomes and expand treatment options for patients with severe aortic valve diseases. These advancements are pivotal in meeting the growing demand for minimally invasive cardiovascular interventions in Japan's aging population. Moreover, Japan has one of the most rapidly aging populations globally. According to the World Economic Forum, in September 2023, In Japan, around 36.23 million people, nearly one-third of the population, are over 65. This aging demographic is highly prone to aortic stenosis and cardiovascular diseases, driving the growth of the transcatheter aortic valve replacement industry.

India transcatheter aortic valve replacement market is growing over the forecast period. Increasing aortic stenosis cases and government initiatives drive the growth of the market. According to the Sage Journals article published in July 2024, in India, approximately 7.3% of the population diagnosed with isolated aortic stenosis is estimated to be eligible for transcatheter aortic valve implantation (TAVI), equating to around 300,000 individuals. This significant pool of potential candidates underscores the growing need for minimally invasive solutions like TAVR.

Latin America Transcatheter Aortic Valve Replacement Market Trends

The Latin America transcatheter aortic valve replacement market is experiencing growth due to the increasing prevalence of cardiovascular diseases, particularly aortic stenosis, driven by an aging population. The life expectancy rises, the demand for minimally invasive procedures like TAVR continues to grow. Additionally, advancements in medical technology and improvements in healthcare infrastructure are enhancing the accessibility and effectiveness of TAVR procedures. These innovations are improving patient outcomes and recovery times, contributing to the expanding adoption of TAVR across the region.

Brazil transcatheter aortic valve replacement market is growing over the forecast period. Increasing cases of aortic stenosis and government initiatives drives the growth of the market. According to the ABC Cardiol article published in 2024, degenerative aortic stenosis, a condition affecting approximately 2% to 5% of adults over the age of 65, has emerged as a significant public health challenge globally. In Brazil, the prevalence of calcific aortic valve disease surged by 201.8% between 1990 and 2019, largely due to the country's aging population. This rising burden of aortic stenosis underscores the growing need for advanced treatment options such as transcatheter aortic valve replacement (TAVR).

Middle East & Africa Transcatheter Aortic Valve Replacement Market Trends

The transcatheter aortic valve replacement market in the Middle East and Africais influenced by the high prevalence of heart diseases, including severe aortic valve conditions. As cardiovascular diseases continue to rise in the region, TAVR procedures are becoming increasingly important for managing these conditions in patients who are at high or intermediate surgical risk. This trend underscores the growing adoption of advanced cardiovascular interventions across the Middle East and Africa.

Saudi Arabia transcatheter aortic valve replacement market is expected to grow over the forecast period. Increasing CVD incidence and government initiatives drives the growth of the market. According to the article published BioMed Central Ltd article published in March 2024, In Saudi Arabia, the prevalence of cardiovascular disease (CVD) among individuals aged 15 years and older is approximately 1.6%, highlighting a significant health burden within the population. With the aging demographic and the associated increase in aortic stenosis cases, the demand for advanced treatment options like (TAVR) is rising.

Key Transcatheter Aortic Valve Replacement Company Insights:

Key players operating in the transcatheter aortic valve replacement market are undertaking various initiatives to strengthen their market presence and increase the reach of their implantation procedures and services. Strategies such as expansion activities and partnerships are key in propelling market growth.

Recent Developments

• In March 2024, Medtronic plc announced that the U.S. Food and Drug Administration (FDA) approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for treating symptomatic severe aortic stenosis. The new Evolut FX+ TAVR system retains the valve performance benefits of the previous Evolut TAVR platform and is designed to enhance coronary access.

• In June 2023, JenaValve Technology, Inc., a leading innovator in transcatheter aortic valve replacement (TAVR) systems, has entered into a strategic partnership with egnite, Inc., a digital health company focused on cardiovascular care. This collaboration is designed to deepen insights into the care models and outcomes for patients suffering from aortic regurgitation (AR), aiming to drive improvements in treatment strategies and patient management.

• In January 2024, Eisenhower Health became the first hospital in the U.S. to be designated as an Edwards Benchmark Program Case Observation Site for treating aortic stenosis in patients undergoing transcatheter aortic valve replacement.

Transcatheter Aortic Valve Replacement Market Report Scope

Global Transcatheter Aortic Valve Replacement Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global transcatheter aortic valve replacement market report based on implantation procedure, material, mechanism, end use, and region.

• Implantation Procedure Outlook (Revenue, USD Billion, 2018 - 2030­)

  • Transfemoral

  • Transapical

  • Transaortic

• Material Outlook (Revenue, USD Billion, 2018 - 2030)

  • Nitinol

  • Cobalt chromium

  • Stainless steel

  • Others

• Mechanism Outlook (Revenue, USD Billion, 2018 - 2030)

  • Balloon-expandable

  • Self-expandable

• End Use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Hospitals

  • Ambulatory Surgical Centers

  • Others

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait